Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888602 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Effects of Psyllium on Blood Glucose
A NA study, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT00888602: Completed NA study, sponsored by Procter and Gamble.
NCT00888602 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888602, a NA study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is an open label, single use, randomized, 4-period cross-over study. In each period, subjects will receive one of 4 test combinations. Blood will be drawn prior to study product consumption and following study product consumption for glucose measures.
Interventions
- OTHER Meal
- DIETARY_SUPPLEMENT 3.4 g psyllium
- DIETARY_SUPPLEMENT 6.8 g psyllium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-05 |
| Phase | NA |
What the finished NCT00888602 record still lists
NCT00888602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Meal is the first listed.
NCT00888602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00888602 about?
NCT00888602 is a clinical study titled "Study to Evaluate the Effects of Psyllium on Blood Glucose". This is an open label, single use, randomized, 4-period cross-over study. In each period, subjects will receive one of 4 test combinations. Blood will be drawn prior to study product consumption and following study product consumption for glucose measures.
What is the current status of trial NCT00888602?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2009-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00888602?
The interventions under investigation include: Meal (OTHER), 3.4 g psyllium (DIETARY_SUPPLEMENT), 6.8 g psyllium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00888602?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00888602's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia